Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, DMK Pharmaceuticals's Enterprise Value is $-6.66 Mil.
DMK Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 was $-17.36 Mil. Therefore, DMK Pharmaceuticals's EV-to-EBIT ratio for today is 0.38.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, DMK Pharmaceuticals's Enterprise Value is $-6.66 Mil.
DMK Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Sep. 2023 was $-16.72 Mil. Therefore, DMK Pharmaceuticals's EV-to-EBITDA ratio for today is 0.40.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, DMK Pharmaceuticals's Enterprise Value is $-6.66 Mil.
DMK Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Sep. 2023 was $3.62 Mil. Therefore, DMK Pharmaceuticals's EV-to-Revenue ratio for today is -1.84.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
DMK Pharmaceuticals (OTCPK:DMKPQ) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
DMK Pharmaceuticals's current Enterprise Value is $-6.66 Mil.
DMK Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-17.36 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
DMK Pharmaceuticals's current Enterprise Value is $-6.66 Mil.
DMK Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-16.72 Mil.
DMK Pharmaceuticals's current Enterprise Value is $-6.66 Mil.
DMK Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.62 Mil.
DMK Pharmaceuticals's current Enterprise Value is $-6.66 Mil.
DMK Pharmaceuticals's Cash Flow from Operations for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-9.38 Mil.
DMK Pharmaceuticals's current Enterprise Value is $-6.66 Mil.
DMK Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-9.47 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DMK Pharmaceuticals Enterprise Value Related Terms
DMK Pharmaceuticals Enterprise Value Historical Data
* Premium members only.
The historical data trend for DMK Pharmaceuticals's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DMKPQ vs CNNC, THCT, VFRM: Enterprise Value Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, DMK Pharmaceuticals's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DMK Pharmaceuticals Enterprise Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, DMK Pharmaceuticals's Enterprise Value distribution charts can be found below:
* The bar in red indicates where DMK Pharmaceuticals's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
DMK Pharmaceuticals's Enterprise Value for the fiscal year that ended in Dec. 2022 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DMK Pharmaceuticals (DMKPQ) has a Enterprise Value of $-6.66 Mil as of Jun. 27, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on DMK Pharmaceuticals and its competitors.
Is DMK Pharmaceuticals' Enterprise Value too high?
DMK Pharmaceuticals' current Enterprise Value is $-6.66 Mil. Overall, DMK Pharmaceuticals has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does DMK Pharmaceuticals' Enterprise Value compare to CNNC and THCT?
DMK Pharmaceuticals' Enterprise Value of $-6.66 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Drug Manufacturers company?
A good Enterprise Value depends on the Drug Manufacturers industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on DMK Pharmaceuticals and its competitors. DMK Pharmaceuticals's current Enterprise Value is $-6.66 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DMK Pharmaceuticals stock overvalued right now?
DMK Pharmaceuticals (DMKPQ) has a current Enterprise Value of $-6.66 Mil. The current Enterprise Value is $-6.66 Mil. DMK Pharmaceuticals' overall GF Score™ is 16/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For DMK Pharmaceuticals (DMKPQ), the current Enterprise Value is $-6.66 Mil as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
DMK Pharmaceuticals Corp Formerly Adamis Pharmaceuticals Corp is a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. Its products and product candidates in the allergy, respiratory, and opioid overdose markets include SYMJEPI (epinephrine) Injection 0.3mg and Injection 0.15mg for use in the emergency treatment of acute allergic reactions, including anaphylaxis; a naloxone injection product candidate, ZIMHI, based on the approved Symject injection device and intended for the treatment of opioid overdose; Tempol, an investigational drug; and a Beclomethasone metered dose inhaler product candidate (APC-400) intended for the treatment of Covid-19.
16GF Score
Get the complete analysis for DMKPQ
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DMKPQ has been successfully added to your 
